His research interests lie in the design of metallodrugs with novel mechanisms of action.ġ. He is also a Fellow of the European Academy of Sciences, and Honorary Fellow of the Chemical Research Society of India, and the Chinese Chemical Society. He is a Fellow of the Royal Society of Chemistry (FRSC), Royal Society of Edinburgh (FRSE) and the Royal Society of London (FRS), and an EPSRC RISE Fellow (Recognising Inspirational Scientists and Engineers). Then he became Head of the Department of Chemistry at the University of Warwick, where he is now a Professor. From 1973–96 he was Lecturer, Reader and Professor at Birkbeck College, University of London, and from 1996–2007 Crum Brown Chair of Chemistry at the University of Edinburgh. Subsequently he was an MRC Research Fellow at the University of Cambridge and National Institute for Medical Research. Professor Peter Sadler obtained his BA, MA and DPhil at the University of Oxford. He has particular interests in molecular-ligation materials technology using Chinese natural products. He then set up his own company in China specialising in metal–ligand type catalysts, and metal-ligating materials and related technologies, which now employs over 40 members of staff across several sites. After 2.5 years of postdoctoral research at Oxford University with Professor John Brown FRS and Professor Michael Mingos FRS, he worked for Abingdon-based company PhosphonicS from 2008–2016. Notable was his development of a series of patented organometallic ‘XuPHOS’ catalysts. He then undertook a PhD in Organic Chemistry at Warwick University under the supervision of Professor Martin Wills, part funded by the phosphorus reagent-specialist Rhodia in partnership with an overseas research scholarship (ORS), which he completed in 2005. After completing his BSc degree at Huaqiao University, he moved to the UK and obtained an MS in Finance and Investment Management at The University of Aberdeen. His research interests lie in the design and mechanism of action of photoactivatable metallodrugs, especially the design and synthesis of targeted anticancer and antimicrobial agents, and use of analytical techniques such as microscopy, high resolution mass spectrometry, multinuclear NMR spectroscopy, and synchrotron X-ray mapping techniques.ĭr Yingjian Xu is the Chief Executive Officer of GoldenKeys High-tech Materials Co., Ltd, Honorary Professor in the Department of Chemistry, University of Warwick, and a Fellow of the Royal Society of Chemistry. He is an EPSRC Molecular and Analytical Sciences CDT PhD CASE student at the University of Warwick collaborating on metallodrug design with the Golden Keys High-tech Materials Co., Ltd (Guian, China).
![goldenkey niu logo goldenkey niu logo](https://cedu.news.niu.edu/wp-content/uploads/sites/3/2020/02/golden-apple-logo-2.jpg)
Mr Oliver Carter obtained his MChem in 2018 from the University of Warwick. Investigations of mineral deposits in biology, with their often inherent heterogeneity and tendency to become chemically-modified on isolation, are highly challenging, but new methods for their study, including in intact tissues, hold promise for future advances. Minerals have a unique ability to interact with viruses, microbes and macro-biomolecules through multipoint ionic and/or non-covalent contacts, with potential for novel applications in therapy and biotechnology.
![goldenkey niu logo goldenkey niu logo](https://odotoo.com/2016odotoo/wp-content/uploads/2020/10/30.jpg)
Moreover, 3D mineral particles (including hybrid organo-minerals) can have reactive cavities, and some minerals have dynamic movement of metal ions, anions, and other molecules within their structures. Such surfaces have novel properties compared to single metal centres. They introduce new strategies for medical applications. Metal and mineral surfaces on scales from milli-to nanometres, either natural or synthetic, are patterned or can be modified with hydrophilic/hydrophobic and ionic/covalent target-recognition sites.
![goldenkey niu logo goldenkey niu logo](https://www.goldenkey.org/wp-content/uploads/2019/09/233-Oakland-University.jpg)
Natural minerals (‘stone drugs’) have been used in traditional Chinese medicines for over 2000 years, but there is potential for modern-day use of inorganic minerals to combat viral infections, antimicrobial resistance, and for other areas in need of new therapies and diagnostic aids.